Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

ASTELLAS PHARMA INC

(4503)
My previous session
Most popular
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Astellas Pharma : buys Potenza Therapeutics for up to $405m

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/18/2018 | 04:50am EDT

Japanese pharmaceutical company Astellas Pharma has acquired US-based Potenza Therapeutics for a total consideration of up to $405m.

The deal is made possible as Astellas exercised its option to buy Potenza Therapeutics under a collaboration agreement signed in 2015 for the development of new immuno-oncology (IO) therapies.

Astellas made an upfront payment of $164.6m; Potenza will be eligible for additional payment of up to $240.1m dependent on the progress of different programmes in clinical development.

Following the completion of the transaction, Potenza has become a wholly-owned subsidiary of Astellas.

Astellas Pharma president and CEO Kenji Yasukawa said: In oncology, Astellas has focused on developing treatments for unmet medical needs with novel mechanisms of action and modalities.

We believe the novel assets we have developed with Potenza have the potential to make an even more pronounced difference for patients in need.

Over their alliance period, Astellas and Potenza discovered and developed three investigational new drugs (INDs) ASP8374/PTZ-201, ASP1948/PTZ-329 and ASP1951/PTZ-522.

The drug candidates are said to have the potential to treat a variety of cancers non-responsive or resistant to the current generation of IO therapies.

ASP8374/PTZ-201 is an immune checkpoint inhibitor, while ASP1948/PTZ-329 inhibits Treg function. Both the compounds are undergoing Phase I clinical trials.

ASP1951/PTZ-522 is a GITR agonistic antibody that holds investigational new drug clearance.

Potenza Therapeutics president and CEO Dan Hicklin said: Over the past three and a half years, we have enjoyed a successful and productive partnership with Astellas.

I am pleased that these therapies will now have access to the resources of a large international company, with world-class R&D and the strategic and financial backing to support the development of these innovative potential new medicines for cancer patients in need.

The clinical IO therapies resulting from the partnership are expected to enable combinations with Astellas existing non-IO programmes for life cycle management and future IO combinations.

(c) 2018 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC
03/19ASTELLAS PHARMA : NapaJen Pharma and Astellas Pharma Establish Research Collabor..
AQ
03/19ASTELLAS PHARMA : Launches PROGRAF Granules in the U.S. for Pediatric Liver, Hea..
AQ
03/05AMGEN ASTELLAS - EVENITY SUBCUTANEOUS INJECTION 105 mg SYRINGE LAUNCHED IN JA..
AQ
03/04ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
AQ
03/01ASTELLAS PHARMA : Announces Acceptance of XOSPATATM for Regulatory Review by the..
AQ
02/21ASTELLAS PHARMA : and WiserCare Announce Collaboration to Improve Patient Experi..
AQ
02/17Cash-hoarding Japanese firms please investors as share buybacks hit record
RE
02/14PFIZER : Phase 3 ARCHES Trial Shows XTANDI (enzalutamide) Significantly Improved..
AQ
02/13PFIZER INC. : - Phase 3 ARCHES Trial Shows XTANDI Significantly Improved Radiogr..
AQ
02/12PFIZER INC. : - Phase 3 ARCHES Trial Shows XTANDI Significantly Improved Radiogr..
AQ
More news
Financials (JPY)
Sales 2019 1 304 B
EBIT 2019 270 B
Net income 2019 213 B
Finance 2019 367 B
Yield 2019 2,23%
P/E ratio 2019 15,42
P/E ratio 2020 17,21
EV / Sales 2019 2,38x
EV / Sales 2020 2,41x
Capitalization 3 471 B
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 1 966  JPY
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Chikashi Takeda Chief Financial Officer
Mitsunori Matsuda General Manager-Pharmaceutical Technology
Tomokazu Fujisawa Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC26.94%31 027
JOHNSON & JOHNSON7.28%365 252
NOVARTIS10.99%237 519
ROCHE HOLDING LTD.11.34%233 250
PFIZER-3.09%232 121
MERCK AND COMPANY7.20%209 982